^
Association details:
| Biomarker: | CD22 underexpression + BCL2 overexpression |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | Besponsa (inotuzumab ozogamicin) (DNA replication inhibitor, CD22-targeted antibody-drug conjugate) |
| Direction: | Resistant |
Evidence:
Source:
Title:
CD22low/Bcl-2high Expression Identifies Poor Response to Inotuzumab in Relapsed/ Refractory Acute Lymphoblastic Leukemia
Published date:
11/04/2021
Excerpt:
Inotuzumab ozogamicin (InO)...In order to identify better predictors of response to InO, we analyzed 68 samples from 28 patients with multiply R/R ALL enrolled in Children’s Oncology Group trial AALL1621 (NCT02981628)...CD22high expression predicting good response to InO versus CD22low/Bcl-2high expression predicting poor response.
DOI:
10.1182/blood-2021-149037
Trial ID:
